The Auτonomy Study is a collaboration between kiːelements and Janssen, focused on evaluating the safety and effectiveness of an investigational medicine for early Alzheimer’s Disease. This condition is marked by a gradual decline in cognitive abilities, impacting memory, comprehension, and clear thinking. With limited treatment options available, the study represents a critical opportunity to explore the potential benefits of a new investigational medicine.